References
- Antman KH, Schiff PB and Pass HI Cancer: Principles and Practice of Oncology. 5th edition ed. Philadelphia: Lippincott, 1997; 1853-78
- DiBonito L, Falconieri G, Colautti I, Bonifacio Gori D, Dudine S, Giarelli L. Cytopathology of malignant mesothelioma: a study of its patterns and histological bases. Diagn Cytopathol 1993;9:25-31 https://doi.org/10.1002/dc.2840090106
- Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 1997;111:106-9 https://doi.org/10.1378/chest.111.1.106
- Teirstein AS. Diagnosing malignant pleural mesothelioma. Chest 1998;114:666-7 https://doi.org/10.1378/chest.114.3.666
- Whitaker D, Shilkin KB. Mesotheliomas. Gray W 2nd ed. New York: Churchill Livingstone, 1995; 195-224
- Whitaker D, Shilkin KB. Early diagnosis of malignant mesothelioma: the contribution of effusion and fine needle aspiration cytology and ancillary techniques. New York: Garland Law Publishing, 1989; 71-115
- Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 2002;21:5450-61 https://doi.org/10.1038/sj.onc.1205605
- Marsit CJ, Houseman EA, Christensen BC, et al. Examination of a CpG island methylator phenotype and implications of methylation profiles in solid tumors. Cancer Res 2006;66:10621-9 https://doi.org/10.1158/0008-5472.CAN-06-1687
- Jair KW, Bachman KE, Suzuki H, et al. De novo CpG island methylation in human cancer cells. Cancer Res 2006;66:682-92 https://doi.org/10.1158/0008-5472.CAN-05-1980
- Fujiwara K, Fujimoto N, Tabata M, et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 2005;11:1219-25
- Wang J, Lee JJ, Wang L, et al. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res 2004;10:6119-25 https://doi.org/10.1158/1078-0432.CCR-04-0652
- Toyooka S, Suzuki M, Maruyama R, et al. The relationship between aberrant methylation and survival in non-smallcell lung cancers. Br J Cancer 2004;91:771-4 https://doi.org/10.1038/sj.bjc.6602013
- Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis 2002;23:1127-30 https://doi.org/10.1093/carcin/23.7.1127
- Wong L, Zhou J, Anderson D, Kratzke RA. Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer 2002;38:131-6 https://doi.org/10.1016/S0169-5002(02)00178-2
- Toyooka S, Carbone M, Toyooka KO, et al. Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells. Oncogene 2002;21:4340-4 https://doi.org/10.1038/sj.onc.1205381
- Toyooka S, Pass HI, Shivapurkar N, et al. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res 2001;61:5727-30
- Chan EC, Lam SY, Tsang KW, et al. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage. Clin Cancer Res 2002;8:3741-6
- Toyooka S, Toyooka KO, Maruyama R, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther 2001;1:61-7
- Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y, Motoyama T. Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 2003;94:589-92 https://doi.org/10.1111/j.1349-7006.2003.tb01487.x
- Harden SV, Tokumaru Y, Westra WH, et al. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 2003;9:1370-5
- Zhou JX, Niehans GA, Shar A, Rubins JB, Frizelle SP, Kratzke RA. Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer. Lung Cancer 2001;32:27-38 https://doi.org/10.1016/S0169-5002(00)00210-5
- Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-6 https://doi.org/10.1073/pnas.93.18.9821
- Fackler MJ, McVeigh M, Evron E, et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003;107:970-5 https://doi.org/10.1002/ijc.11508
- Pu RT, Laitala LE, Alli PM, Fackler MJ, Sukumar S, Clark DP. Methylation profiling of benign and malignant breast lesions and its application to cytopathology. Mod Pathol 2003;16:1095-101 https://doi.org/10.1097/01.MP.0000095782.79895.E2
- Pu RT, Sheng ZM, Michael CW, Rhode MG, Clark DP, O'Leary TJ. Methylation profiling of mesothelioma using real-time methylation-specific PCR: a pilot study. Diagn Cytopathol 2007;35:498-502 https://doi.org/10.1002/dc.20692
- Kobayashi N, Toyooka S, Yanai H, et al. Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. Lung Cancer 2008 [EPub ahead of print]
- Kim H, Kwon YM, Kim JS, et al. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J Clin Oncol 2004;22:2363-70 https://doi.org/10.1200/JCO.2004.10.077
- Topaloglu O, Hoque MO, Tokumaru Y, et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 2004;10:2284-8 https://doi.org/10.1158/1078-0432.CCR-1111-3
- Benlloch S, Galbis-Caravajal JM, Martin C, et al. Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion. Cancer 2006;107:1859-65 https://doi.org/10.1002/cncr.22190
- Fischer JR, Ohnmacht U, Rieger N, et al. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 2006;54:109-16 https://doi.org/10.1016/j.lungcan.2006.06.017
- Ramirez JL, Rosell R, Taron M, et al. 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatinplus- gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J Clin Oncol 2005;23:9105-12 https://doi.org/10.1200/JCO.2005.02.2905
- Ramirez JL, Sarries C, de Castro PL, et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett 2003;193:207-16 https://doi.org/10.1016/S0304-3835(02)00740-1
- Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70
Cited by
- Utility of Promoter Hypermethylation for Differentiating Malignant and Benign Effusions in Liquid-Based Cytology Specimens vol.44, pp.3, 2010, https://doi.org/10.4132/koreanjpathol.2010.44.3.315